Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.40 USD
Change Today +0.01 / 0.23%
Volume 2.3K
VNRX On Other Exchanges
As of 4:15 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

volitionrx ltd (VNRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/17/15 - $5.30
52 Week Low
05/6/15 - $2.81
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VOLITIONRX LTD (VNRX)

Related News

No related news articles were found.

volitionrx ltd (VNRX) Related Businessweek News

No Related Businessweek News Found

volitionrx ltd (VNRX) Details

VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is involved in the development of 20 epigenetic NuQ blood assays based on its Nucleosomics biomarker platform. It develops two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer. The company also develops nine blood assays in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; five blood assays in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts; and a NuQ-T assay to detect cancer by detecting total blood nucleosome levels, as well as offers research kits. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.

10 Employees
Last Reported Date: 03/18/15

volitionrx ltd (VNRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Medical Officer and Head of US Operatio...
Total Annual Compensation: --
Total Annual Compensation: --
Business Development Director
Total Annual Compensation: --
Secretary of Hypergenomics Pte Limited and Di...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

volitionrx ltd (VNRX) Key Developments

VolitionRX Ltd Presents at Aegis Capital Corp 2015 Growth Conference, Oct-09-2015 01:30 PM

VolitionRX Ltd Presents at Aegis Capital Corp 2015 Growth Conference, Oct-09-2015 01:30 PM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States.

VolitionRx Limited Announces First CE Mark for NuQ(R) Blood Assay for Detection of Colorectal Cancer

VolitionRx Limited announced the Company's first CE Mark for its blood-based diagnostic assay, NuQX001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals. The NuQX001S assay is the first to be CE Marked out of a suite of NuQ assays developed by VolitionRx targeting different epigenetic modifications that indicate that cancer is present. The Company plans to offer a commercial test consisting of a panel of 4-6 individual ELISA assays; it is currently conducting ongoing clinical trials and following the CE compliance process on further assays in order to refine the make-up of the panel and produce the accuracy detection rates. VolitionRx anticipates launching its panel of CE Marked assays for clinical use in Europe during 2016. This announcement follows the presentation earlier this month of interim data of a 4,800-subject trial, which demonstrated that VolitionRx's NuQ blood tests detected 81% of colorectal cancers at 78% specificity equally well for both for early- and late-stage cancers, as well as 63% of potentially pre-cancerous adenomas and 67% of high-risk adenomas - the most likely to become cancerous.

VolitionRX Ltd to Approve and Adopt Amendment and Restatement of Bylaws

VolitionRX Ltd. will approve and adopt the amendment and restatement of the company's Bylaws at the Annual Meeting to be held on October 30, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNRX:US $4.40 USD +0.01

VNRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation VNRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5,326.7x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,689.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VOLITIONRX LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at